GSK today announces that Dr Moncef Slaoui, Chairman, Vaccines, has indicated to the Board his intention to retire from the Company in 2017.
The Board supports Dr Slaoui’s decision and has agreed he will retire on 30 June 2017.
Dr Slaoui will remain a member of the Board until 31 March 2017. From 1 April 2017 until his retirement on 30 June 2017, he will serve as an advisor to both GSK and the Board. Dr Slaoui joined GSK in 1988 and the Board in 2006.
Philip Hampton, Chairman, GSK, said: “On behalf of the Board, I would like to thank Moncef for his great contribution to the company. He has been personally involved in the discovery and development of some of our most innovative vaccines and spearheaded the overhaul of GSK’s pharmaceutical R&D. GSK has been fortunate to benefit from Moncef’s considerable scientific and technical experience over many years and I’m pleased that during his remaining time, he will continue to provide this valuable expertise to the Company.”
Source: GSK
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
